The stock is bouncing back from a recent 52-week low.
The company is poised to report a critical set of clinical data in the coming months.
A notable analyst upgrade had investors piling into this clinical-stage biotech stock today.
Investors appear to be getting into position ahead of a major upcoming catalyst.
SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab...
SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab...
The Schall Law Firm, a national shareholder rights litigation firm, announces it is investigating potential breaches of fiduciary duties by the management of Allakos, Inc. (“Allakos”) (NASDAQ: ALLK...
The Schall Law Firm, a national shareholder rights litigation firm, announces it is investigating potential breaches of fiduciary duties by the management of Allakos, Inc. (“Allakos”) (NASDAQ: ALLK...